Forecast: Respiratory System Medicine Sales in Australia

Between 2013 and 2023, respiratory system medicine sales in Australia exhibited significant growth, rising from AUD 638 million to AUD 1,210 million. A substantial uptick was noted in the years 2019-2020, with a 24.73% and 17.51% year-on-year increase, respectively. The average Compound Annual Growth Rate (CAGR) over the last five years stood at 10.6%. This steep rise indicates a robust market expansion in this segment, especially noticeable during the pandemic years.

In 2023, the value of respiratory system medicine sales was AUD 1,210 million. Y-o-Y growth rates for the last two years were 5.42% in 2022 and 5.06% in 2023.

With forecasted sales reaching AUD 1,490 million by 2028, the market anticipates a more moderate CAGR of 3.4% over the next five years, reflecting an 18.21% growth rate.

Future trends to watch for include:

• Increased investment in innovative respiratory treatments and therapies
• The impact of healthcare policies on drug pricing and accessibility
• Potential new entrants and competition in the market
• Technological advancements in drug delivery systems